Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the transaction, the chief financial officer now directly owns 50,566 shares in the company, valued at approximately $63,713.16. This represents a 43.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Regulus Therapeutics Stock Performance

Shares of NASDAQ:RGLS traded up $0.05 during midday trading on Wednesday, hitting $1.27. 283,082 shares of the company’s stock traded hands, compared to its average volume of 348,120. The firm’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.59. Regulus Therapeutics Inc. has a twelve month low of $1.08 and a twelve month high of $3.79. The company has a market cap of $83.19 million, a PE ratio of -1.19 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics in the second quarter valued at $352,000. Rhumbline Advisers acquired a new position in Regulus Therapeutics in the 2nd quarter worth $136,000. Renaissance Technologies LLC boosted its position in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 42,600 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter valued at about $33,000. Finally, Creative Planning purchased a new stake in shares of Regulus Therapeutics during the third quarter worth about $26,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.